Marksans Pharma's Goa unit concludes USFDA inspection with observations
On conclusion of the inspection, the Company has received 5 inspectional observations in form 483. There is no data integrity observation. The Company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content